APTX · Aptinyx Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $1.00M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $16.09M | - | $10.01M | $11.91M | $13.60M | - | $16.28M | $14.80M | $10.31M | - |
| SG&A | $4.23M | - | $4.65M | $5.20M | $5.78M | - | $4.93M | $5.07M | $4.98M | - |
| Total Operating Expenses | $20.32M | - | $14.66M | $17.11M | $19.38M | - | $21.21M | $19.87M | $15.29M | - |
| D&A | $32.0K | - | - | - | $38.0K | - | $100.0K | $100.0K | $412.0K | - |
| Operating Income | ($20.32M) | - | ($14.66M) | ($17.11M) | ($19.38M) | - | ($21.21M) | ($19.87M) | ($14.29M) | - |
| Interest Expense | $1.03M | - | $854.0K | $757.0K | $477.0K | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($21.07M) | - | ($15.30M) | ($17.67M) | ($19.83M) | - | ($21.23M) | ($19.82M) | ($14.23M) | - |
| EPS - Basic | ($0.31) | - | ($0.31) | ($0.26) | ($0.29) | - | - | - | - | - |
| EPS - Diluted | ($0.31) | - | ($0.23) | ($0.26) | ($0.29) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $44.57M | $56.20M | $66.58M | $85.27M | $100.16M | $106.12M | $125.29M | $129.23M | $146.81M | $141.03M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | $257.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.37M | $724.0K | $474.0K | $2.11M | $1.75M | $622.0K | $3.12M | $434.0K | $1.67M | $1.21M |
| Current Assets | $47.76M | $64.03M | $73.95M | $92.14M | $106.53M | $114.74M | $132.41M | $133.78M | $152.41M | $149.60M |
| Total Assets | $47.96M | $66.68M | $76.20M | $92.31M | $106.65M | $114.93M | $132.65M | $134.17M | $152.89M | $150.61M |
| Current Liabilities | $9.32M | $6.29M | $2.69M | $5.68M | $4.74M | $5.69M | $6.28M | $3.38M | $3.88M | $4.58M |
| Long-term Debt | $19.44M | $22.11M | $24.71M | $24.50M | $24.29M | $14.15M | $14.04M | - | - | - |
| Total Liabilities | $29.71M | $28.40M | $27.41M | $30.21M | $29.17M | $20.17M | $20.61M | $3.41M | $3.95M | $4.70M |
| Stockholders' Equity | $18.26M | $38.28M | $48.79M | $62.10M | $77.48M | $94.76M | $112.04M | $130.76M | $148.94M | $145.91M |
| Retained Earnings | ($373.80M) | ($352.74M) | ($340.68M) | ($325.38M) | ($307.71M) | ($287.89M) | ($268.28M) | ($247.05M) | ($227.23M) | ($213.00M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($11.37M) | - | - | - | ($15.92M) | - | - | - | ($8.98M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $90.0K | - |
| Financing Cash Flow | ($267.0K) | - | - | - | $9.96M | - | - | - | $14.68M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | -1429.0% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -1387.8% | - |
| Net margin | - | - | - | - | - | - | - | - | -1422.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | 1031.4% | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | 497.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -43.9% | - | -20.1% | -19.1% | -18.6% | - | -16.0% | -14.8% | -9.3% | - |
| Return on equity | -115.4% | - | -31.4% | -28.4% | -25.6% | - | -18.9% | -15.2% | -9.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.12 | 10.18 | 27.45 | 16.22 | 22.49 | 20.18 | 21.07 | 39.56 | 39.30 | 32.64 |
| Quick ratio | 5.12 | 10.18 | 27.45 | 16.22 | 22.49 | 20.18 | 21.07 | 39.56 | 39.30 | 32.64 |
| Cash ratio | 4.78 | 8.93 | 24.72 | 15.01 | 21.14 | 18.66 | 19.94 | 38.21 | 37.86 | 30.77 |
| Leverage | ||||||||||
| Debt / Equity | 1.07 | 0.58 | 0.51 | 0.39 | 0.31 | 0.15 | 0.13 | - | - | - |
| Debt / Assets | 0.41 | 0.33 | 0.32 | 0.27 | 0.23 | 0.12 | 0.11 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -19.7x | - | -17.2x | -22.6x | -40.6x | - | - | - | - | - |
| Equity multiplier | 2.63 | 1.74 | 1.56 | 1.49 | 1.38 | 1.21 | 1.18 | 1.03 | 1.03 | 1.03 |
| Liabilities / Assets | 0.62 | 0.43 | 0.36 | 0.33 | 0.27 | 0.18 | 0.16 | 0.03 | 0.03 | 0.03 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | 22.2% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -4.9% | - | 30.9% | 13.9% | -35.6% | - | -85.6% | -57.1% | 5.6% | - |
| Net income growth (YoY) | -6.2% | - | 27.9% | 10.9% | -39.4% | - | -87.3% | -58.3% | 3.3% | - |
| EPS growth (YoY) | -6.9% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -76.4% | -59.6% | -56.5% | -52.5% | -48.0% | -35.1% | 2.1% | 11.5% | 21.6% | 44.0% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aptinyx Inc. against the 5 most active filers in the same SIC group.